Instacart and Advantage Solutions Partner to Give CPGs Real-Time Shelf Visibility at Scale New Partnership Helps CPGs Quickly Identify Gaps, Take Action, and Improve In-Store Execution SAN FRANCISCO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Instacart (NASDAQ: CART) and Advantage Solutions Inc. (NASDAQ: ADV), a leading sales and marketing agency for consumer goods manufacturers and retailers, today announced a strategic partnership to help consumer packaged goods companies (CPGs) of all sizes improve in-store execution. Together, Instacart and Advantage will deliver a transformative solution...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation) and Avadel Pharmaceuticals are celebrating five years of collaboration and dedicated support for early-career sleep researchers and future sleep physicians. In 2021, Avadel became the Young Investigator Research Forum’s (YIRF) inaugural corporate sponsor. Thanks to support from Avadel and other companies, YIRF has empowered dozens of trainees and junior faculty in sleep and circadi...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to five (5) new employees to purchase 165,520 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rul...
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025 – 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REFRESH study also highlights efficacy in those who were new to oxybate or returning to oxybate after discontinuing twice-nightly oxybate – DUBLIN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company f...
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd – Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia – – Initial pharmacokinetic (PK) and comparative bioavailability study to initiate in fourth quarter 2025 with pivotal PK trial planned for second half 2026 – – XWPharma to receive $20 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales – DUBLIN and...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference: Fireside chat on Friday, September 5 at 11:00 a.m. ET.Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside chat on Tuesday, September 9 at 1:05 p.m. ET.H.C. Wainwright 27th Annual Global Investment C...
Moody's Ratings (Moody's) downgraded ModivCare Inc.'s corporate family rating (CFR) to Ca from Caa1 and probability of default rating (PDR) to D-PD from Caa1-PD. At the same time, we downgraded the senior secured bank credit facility rating to Caa3 from B3, the senior secured second lien notes to C ...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Mid-America Apartments, L.P. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 18 August 2025 in which we reassessed the appropriateness of the ratings in th...
A director at Opko Health Inc bought 675,000 shares at 1.320USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Jeff Harsh named new Chief Operating Officer of Advantage Solutions Branded Services business segment Strategic results-driven leader with deep CPG experience and connectivity in retail to succeed Dean General, who will remain at Advantage in newly created role ST. LOUIS, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc (NASDAQ: ADV), announced the appointment of Jeff Harsh as the new Chief Operating Officer of its Branded Services business segment, effective Aug. 25. Harsh will join the company’s executive leadership team and report to CEO Dave Peacock. Harsh comes to Advan...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to eight (8) new employees to purchase 60,400 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule...
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance -- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 -- -- Raises 2025 full year revenue guidance to $265 - $275 million -- -- Received Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH) -- ...
Advantage Solutions Reports Second Quarter 2025 Results Strong profitability growth in Experiential and Retailer Services Advancing transformation initiatives to accelerate AI enablement and improved business insights Expecting improved financial performance and cash generation in the second half of the year Reaffirming 2025 guidance ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage,” “Advantage Solutions,” the “Company,” “we,” or “our”), a leading business solutions provider to consumer goods manufacturers and retailers, today re...
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial (). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerability in up to 200 h...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7 DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 7, 2025, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2025. A live audio webcast of the call can be accessed by visiting the investo...
Advantage Solutions to Participate in The Canaccord Annual Growth Conference on August 12, 2025 ST. LOUIS, July 30, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ GS: ADV) announced today that Dave Peacock, Chief Executive Officer, and Chris Growe, Chief Financial Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference in Boston on Aug. 12, 2025. A live fireside chat with Dave Peacock will be held at noon EDT. The listen-only webcast can be accessed from the Advantage Solutions website at . For more details, contact your Canaccord Genuity representative...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.